Table 2.

Whole brain and segmented CBF and OEF between cohorts

No disease-modifying therapy, median (IQR)Hydroxyurea therapy, median (IQR)Chronic transfusion therapy, median (IQR)P
Cerebral blood flow (N = 11) N = 25 N = 14  
 Whole brain CBF, mL/100 g/min 99.8 (82.7-117.7) 90.8 (74.2-100.2) 87.0 (75.9-96.4) .148 
 Gray matter CBF, mL/100 g/min 112.5 (93.4-130.1) 97.4 (86.7-109.8) 94.3 (87.7-112.8) .312 
 White matter CBF, mL/100 g/min 60.5 (46.1-81.5) 55.5 (46.6-66.6) 51.1 (48.7-55.9) .274 
OEF N = 22 N = 38 N = 22  
 Whole brain OEF, % 42.9 (39.1-49.1)*, 40.7 (34.9-43.6)*, 35.3 (32.2-38.9), <.001 
 Gray matter OEF, % 44.3 (39.2-49.2)*, 41.2 (36.3-44.4)*, 35.0 (33.2-37.7), <.001 
 White matter OEF, % 42.6 (38.1-48.7)*, 39.8 (33.8-43.5)*, 34.1 (30.8-39.2), <.001 
No disease-modifying therapy, median (IQR)Hydroxyurea therapy, median (IQR)Chronic transfusion therapy, median (IQR)P
Cerebral blood flow (N = 11) N = 25 N = 14  
 Whole brain CBF, mL/100 g/min 99.8 (82.7-117.7) 90.8 (74.2-100.2) 87.0 (75.9-96.4) .148 
 Gray matter CBF, mL/100 g/min 112.5 (93.4-130.1) 97.4 (86.7-109.8) 94.3 (87.7-112.8) .312 
 White matter CBF, mL/100 g/min 60.5 (46.1-81.5) 55.5 (46.6-66.6) 51.1 (48.7-55.9) .274 
OEF N = 22 N = 38 N = 22  
 Whole brain OEF, % 42.9 (39.1-49.1)*, 40.7 (34.9-43.6)*, 35.3 (32.2-38.9), <.001 
 Gray matter OEF, % 44.3 (39.2-49.2)*, 41.2 (36.3-44.4)*, 35.0 (33.2-37.7), <.001 
 White matter OEF, % 42.6 (38.1-48.7)*, 39.8 (33.8-43.5)*, 34.1 (30.8-39.2), <.001 
*

Significant difference between cohort not receiving disease-modifying therapy vs cohort receiving HU.

Significant difference between cohort not receiving disease-modifying therapy vs cohort receiving CTT.

Statistically significant.

Significant difference between cohort receiving HU vs cohort receiving CTT.

or Create an Account

Close Modal
Close Modal